Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

(2016) D. A. Vallera et al.   CLINICAL CANCER RESEARCH

HIV-specific CD8+ T cells and HIV eradication

(2016) R. Brad Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

Measuring the latent reservoir in vivo

(2016) Marta Massanella et al.   JOURNAL OF CLINICAL INVESTIGATION

Persistent HIV-1 replication maintains the tissue reservoir during therapy

(2016) Ramon Lorenzo-Redondo et al.   NATURE

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

(2016) Johannes F. Scheid et al.   NATURE

International AIDS Society global scientific strategy: towards an HIV cure 2016

(2016) Steven G Deeks et al.   NATURE MEDICINE

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

(2016) Ann J Hessell et al.   NATURE MEDICINE

PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals

(2016) Riddhima Banga et al.   NATURE MEDICINE

Clonally expanded CD4+T cells can produce infectious HIV-1 in vivo

(2016) Francesco R. Simonetti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

(2016) C.-L. Lu et al.   SCIENCE

Ex VivoBioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+T Cells from Aviremic Patients

(2015) Adam M. Spivak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-1 Integration Landscape during Latent and Active Infection

(2015) Lillian B. Cohn et al.   CELL

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

(2015) M. Anthony Moody et al.   Cell Host & Microbe

FDA Approval: Blinatumomab

(2015) D. Przepiorka et al.   CLINICAL CANCER RESEARCH

Bispecific antibodies

(2015) Roland E. Kontermann et al.   DRUG DISCOVERY TODAY

Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1

(2015) S. Bouchat et al.   EMBO Molecular Medicine

Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells

(2015) Julia A.M. Sung et al.   JOURNAL OF CLINICAL INVESTIGATION

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization

(2015) M. Asokan et al.   JOURNAL OF VIROLOGY

H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat inEx VivoCultures of Resting CD4+T Cells

(2015) Manoj K. Tripathy et al.   JOURNAL OF VIROLOGY

Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs

(2015) Diane L. Bolton et al.   JOURNAL OF VIROLOGY

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

(2015) Matthew R. Gardner et al.   NATURE

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

(2015) Kai Deng et al.   NATURE

B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers

(2015) Yoshinori Fukazawa et al.   NATURE MEDICINE

Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells

(2015) Sanne Skov Jensen et al.   PLoS One

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

(2015) Gurunadh R. Chichili et al.   Science Translational Medicine

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

Towards an HIV-1 cure: measuring the latent reservoir

(2015) Katherine M. Bruner et al.   TRENDS IN MICROBIOLOGY

Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge

(2015) Anton M. Sholukh et al.   VACCINE

Activation and lysis of human CD4 cells latently infected with HIV-1

(2015) Amarendra Pegu et al.   Nature Communications

Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection

(2015) Christa Buckheit Sturdevant et al.   PLoS Pathogens

Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells

(2015) Derek D. Sloan et al.   PLoS Pathogens

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

(2015) Sampa Santra et al.   PLoS Pathogens

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Epigenetic control of HIV-1 post integration latency: implications for therapy

(2015) Amit Kumar et al.   Clinical Epigenetics

Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS

(2015) Maria M. Bednar et al.   Current HIV/AIDS Reports

Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?

(2015) Wen Shi Lee et al.   Frontiers in Immunology

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

(2014) Stylianos Bournazos et al.   CELL

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

(2014) Ariel Halper-Stromberg et al.   CELL

Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies

(2014) Feng Gao et al.   CELL

Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers

(2014) Claudia Blattner et al.   IMMUNITY

Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36

(2014) Ming Sun et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

An HIV Cure

(2014) Anthony S. Fauci et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

(2014) Masashi Shingai et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination

(2014) A. C. Finnefrock et al.   JOURNAL OF IMMUNOLOGY

HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat

(2014) N. M. Archin et al.   JOURNAL OF INFECTIOUS DISEASES

Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection

(2014) P. Acharya et al.   JOURNAL OF VIROLOGY

Quantitation of Replication-Competent HIV-1 in Populations of Resting CD4+ T Cells

(2014) N. Soriano-Sarabia et al.   JOURNAL OF VIROLOGY

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface

(2014) Jinghe Huang et al.   NATURE

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

(2014) Nancie M. Archin et al.   NATURE REVIEWS MICROBIOLOGY

Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

(2014) F. Maldarelli et al.   SCIENCE

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

(2014) A. Pegu et al.   Science Translational Medicine

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

(2014) Julian H. Elliott et al.   PLoS Pathogens

Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy

(2014) Mary F. Kearney et al.   PLoS Pathogens

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure

(2013) Ya-Chi Ho et al.   CELL

An Integrated Overview of HIV-1 Latency

(2013) Debbie S. Ruelas et al.   CELL

Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses

(2013) Justin Pollara et al.   CURRENT HIV RESEARCH

Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells

(2013) R. Wong et al.   HAEMATOLOGICA

Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation

(2013) Michael J. Vinikoor et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity

(2013) M. Veillette et al.   JOURNAL OF VIROLOGY

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques

(2013) C Moog et al.   Mucosal Immunology

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

(2013) Hua-Xin Liao et al.   NATURE

Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant

(2013) Deborah Persaud et al.   NEW ENGLAND JOURNAL OF MEDICINE

High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers

(2013) Olivier Lambotte et al.   PLoS One

The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

(2013) L. Josefsson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV latency and integration site placement in five cell-based models

(2013) Scott Sherrill-Mix et al.   Retrovirology

HIV Latency

(2013) R. F. Siliciano et al.   Cold Spring Harbor Perspectives in Medicine

The T-Cell Response to HIV

(2013) B. Walker et al.   Cold Spring Harbor Perspectives in Medicine

Single Cell Analysis of Lymph Node Tissue from HIV-1 Infected Patients Reveals that the Majority of CD4+ T-cells Contain One HIV-1 DNA Molecule

(2013) Lina Josefsson et al.   PLoS Pathogens

An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients

(2013) Celsa A. Spina et al.   PLoS Pathogens

Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies

(2013) Susanne Eriksson et al.   PLoS Pathogens

Control of HIV Latency by Epigenetic and Non-Epigenetic Mechanisms

(2012) Jonathan Karn et al.   CURRENT HIV RESEARCH

Redefining the Viral Reservoirs that Prevent HIV-1 Eradication

(2012) Evelyn Eisele et al.   IMMUNITY

Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation

(2012) Liang Shan et al.   IMMUNITY

Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production

(2012) Matthieu Perreau et al.   JOURNAL OF EXPERIMENTAL MEDICINE

HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy

(2012) Christine M. Durand et al.   JOURNAL OF INFECTIOUS DISEASES

A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fc RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

(2012) B. Moldt et al.   JOURNAL OF VIROLOGY

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

(2012) M. K. Gleason et al.   MOLECULAR CANCER THERAPEUTICS

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Shock and kill

(2012) Steven G. Deeks   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-HIV Double Variable Domain Immunoglobulins Binding Both gp41 and gp120 for Targeted Delivery of Immunoconjugates

(2012) Ryan B. Craig et al.   PLoS One

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

(2012) N. M. Archin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

(2012) B. Moldt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

(2012) H. Mouquet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Developing strategies for HIV-1 eradication

(2012) Christine M. Durand et al.   TRENDS IN IMMUNOLOGY

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection

(2011) T. Yamamoto et al.   BLOOD

HIV-1 Utilizes the CXCR4 Chemokine Receptor to Infect Multipotent Hematopoietic Stem and Progenitor Cells

(2011) Christoph C. Carter et al.   Cell Host & Microbe

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

(2011) Dirk Nagorsen et al.   EXPERIMENTAL CELL RESEARCH

An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum

(2011) G. Ferrari et al.   JOURNAL OF VIROLOGY

A Panel of IgG1 b12 Variants with Selectively Diminished or Enhanced Affinity for Fc  Receptors To Define the Role of Effector Functions in Protection against HIV

(2011) B. Moldt et al.   JOURNAL OF VIROLOGY

Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells

(2011) J. A. Anderson et al.   JOURNAL OF VIROLOGY

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

(2011) Jason S. McLellan et al.   NATURE

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy

(2011) Cynthia Gay et al.   PLoS One

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

(2011) D. R. Burton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design

(2011) R. Diskin et al.   SCIENCE

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

(2011) J. F. Scheid et al.   SCIENCE

Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection

(2011) Guido Ferrari et al.   PLoS Pathogens

A Dynamic Landscape for Antibody Binding Modulates Antibody-Mediated Neutralization of West Nile Virus

(2011) Kimberly A. Dowd et al.   PLoS Pathogens

Short Communication: Dynamic Constraints on the Second Phase Compartment of HIV-Infected Cells

(2010) Adam M. Spivak et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Evidence for the cure of HIV infection by CCR5 32/ 32 stem cell transplantation

(2010) K. Allers et al.   BLOOD

Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion

(2010) Syd Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs

(2010) Christoph C Carter et al.   NATURE MEDICINE

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

(2010) T. Zhou et al.   SCIENCE

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

(2009) Nilu Goonetilleke et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention

(2009) Daniel E. Kaufmann et al.   JOURNAL OF IMMUNOLOGY

Kinetics of Expansion of Epitope-Specific T Cell Responses during Primary HIV-1 Infection

(2009) E. L. Turnbull et al.   JOURNAL OF IMMUNOLOGY

Persistent Low‐Level Viremia in HIV‐1 Elite Controllers and Relationship to Immunologic Parameters

(2009) Florencia Pereyra et al.   JOURNAL OF INFECTIOUS DISEASES

Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells

(2009) H. Streeck et al.   JOURNAL OF VIROLOGY

Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

(2009) A. J. Hessell et al.   JOURNAL OF VIROLOGY

Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy

(2009) T. P. Brennan et al.   JOURNAL OF VIROLOGY

Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections

(2009) A. R. Stacey et al.   JOURNAL OF VIROLOGY

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

(2009) Ann J Hessell et al.   NATURE MEDICINE

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

HIV-1-specific antibody responses during acute and chronic HIV-1 infection

(2009) Georgia D Tomaras et al.   Current Opinion in HIV and AIDS

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

(2009) Ann J. Hessell et al.   PLoS Pathogens

Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy

(2008) H. Hatano et al.   JOURNAL OF VIROLOGY

Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naive Human Immunodeficiency Virus Controllers

(2008) M. Mahalanabis et al.   JOURNAL OF VIROLOGY

Enhancing SIV-specific immunity in vivo by PD-1 blockade

(2008) Vijayakumar Velu et al.   NATURE

Antigen Load and Viral Sequence Diversification Determine the Functional Profile of HIV-1–Specific CD8+ T Cells

(2008) Hendrik Streeck et al.   PLOS MEDICINE